Firstly CHF is one of the most lucrative of the applications of MSB's stem cells. The program has already been refined to concentrate on the most lucrative. How did you not know this?
So you worked with COH and CSL?
They are indeed in a different sector to MSB because stem cell technology is an entirely new sector just as those entities have been pioneers in their own way, but MSB is paradigm-shifting.
You're sorry? I'm sorry you haven't picked up that MSB is world leader in the sector and in particular has dominance over inflammatory conditions, and based on potential revenue and market size it could well become another COH and CSL. Sorry you missed this important point with all your gloating.
More than happy to continue to watch from the sidelines and read everybody's view and laugh (sorry I feel for those sucked in).
Yes you noble creature, you are indeed a value investor, only interested in stocks already showing a profit....just like your pal
@madamswer which means you really shouldn't hang around biotechs because they have a long lead time and clearly you don't have any patience. All you can do is harp on about the shareprice.
MSB is in the business of saving lives right now in Japan with the aGVHD application, and there will be future fast tracking of CHF in Japan as they accept stage 2 efficacy as sufficient to go to market. But go ahead, you seem proud of your ignorance about the fact that MSB is also engaged in discussions with Celgene who thankfully, is in the same space (unlike Teva).
You also shouldn't assume that the SP is a true indicator of future returns but it seems you have.
Forgive me, I have this old fashioned view that investors back sound companies and assist them with developing and making a profit.
I'm can't think what your motivation is behind the sneery remarks but I'm sure of one thing: shorters never reveal themselves in here and smugly negative so called value investing posters can't be relied on for a fair assessment of MSB.
(20min delay)